| |
FDG study (N = 22)
|
FLT study (N = 27)
|
|---|
|
N (%)
|
Mean (range)
|
N (%)
|
Mean (range)
|
|---|
|
Diagnosis
|
|
Invasive ductal
|
20 (91%)
| |
20 (74%)
| |
|
Invasive lobular
|
2 (9%)
| |
7 (26%)
| |
|
Tumor size (cm)
| |
2.6 (0.7–7.5)
| |
3.1 (1.1–7.6)*
|
|
T Stage
|
|
T1
|
9 (41%)
| |
8 (30%)
| |
|
T2
|
12 (55%)
| |
15 (56%)
| |
|
T3
|
1 (5%)
| |
3 (11%)
| |
|
X
|
–
| |
1 (4%)
| |
|
ER+
|
22 (100%)
| |
27 (100%)
| |
|
PR+
|
20 (91%)
| |
22 (81%)
| |
|
Her2-
|
22 (100%)
| |
26 (96%)†
| |
|
Ki-67 (Biopsy)
|
|
All
| |
25.4 (1.0–72.9)
| |
20.6 (4–54)
|
|
Ductal
| |
26.5 (1–72.9)
| |
23.5 (6–54)
|
|
Lobular
| |
14 (9.2–18.8)
| |
12.3 (4–23)
|
|
Ki-67 (at surgery)
|
|
All
| |
8.7 (1.0–31.4)
| |
7.9 (0–41)
|
|
Ductal
| |
9.1 (< 1.0–31.4)
| |
9.3 (0–41)
|
|
Lobular
| |
4.4 (3–5.9)
| |
4.1 (0–20.3)
|
|
Ki-67 ≤ 10% (at surgery)
|
|
All
|
17 (77%)
| |
21 (78%)
| |
|
Ductal
|
15 (75%)
| |
15 (75%)
| |
|
Lobular
|
2 (100%)
| |
6 (86%)
| |
- *Tumor sized by MRI in all but one patient. That patient had a lesion size of 1.1 cm by contrast enhanced CT
- †1 patient was scored as HER2 equivocal, but no plan for treatment change
